GOODMAN & GILMAN'S 13th EDITION
Enhanced Original Pharmacology Study Guide
High-yield review • mechanisms • therapeutic reasoning • exam-style practice
Based on the publicly visible preview and chapter framework of the referenced Stuvia listing, plus authoritative
drug-development/labeling context.
This is an original study guide. It does not reproduce or reconstruct the paid test bank, and none of the practice questions below are claimed to be
actual or verified exam questions.
Prepared: September 2026
Goodman & Gilman 13e — Original Enhanced Study Guide Page 1
, 1. MASTER EXAM BLUEPRINT
The referenced listing describes an 810-page, 2020/2021 test-bank document and its public preview begins with Chapter 1. The
visible preview emphasizes pharmacology foundations, controlled-drug scheduling, clinical-trial phases, generic
substitution/bioavailability, medication reconciliation, and continuing pharmacology education. ■cite■turn0view0■
The 13th edition itself is organized into nine major sections and 71 chapters, spanning general principles, neuropharmacology,
cardiovascular/renal/pulmonary therapy, inflammation and hematopoiesis, hormones, GI therapy, anti-infective chemotherapy,
cancer pharmacotherapy, and special systems. ■cite■turn0search0■turn1search3■
Section High-yield domains
I. General Principles drug development; PK; PD; toxicity; transporters; metabolism; pharmacogenetics
II. Neuropharmacology autonomic drugs; CNS transmitters; depression/anxiety; psychosis; epilepsy; degeneration; opioids; anesthesia
III. Renal/Cardio/Pulmonary diuretics; RAAS; ischemia; hypertension; heart failure; arrhythmias; PAH; coagulation; lipids
IV. Inflammation/Immune immunosuppression; vaccines; eicosanoids; NSAIDs; histamine; pulmonary drugs; hematopoiesis
V. Endocrine pituitary; thyroid; reproductive hormones; adrenal steroids; diabetes; bone/mineral drugs
VI. GI acid/ulcer/GERD; motility; emesis; biliary/pancreatic disease; IBD
VII. Infectious disease antimicrobial principles; malaria; protozoa; helminths; antibacterials; TB; fungi; viruses; HIV
VIII. Cancer cytotoxic agents; targeted therapy; monoclonal antibodies; kinase inhibitors; endocrine therapy
IX. Special systems ocular; dermatologic; environmental toxicology
2. GENERAL PRINCIPLES: THE CORE LANGUAGE OF
PHARMACOLOGY
Pharmacokinetics (PK) asks what the body does to the drug: absorption, distribution, metabolism, and excretion.
Pharmacodynamics (PD) asks what the drug does to the body: receptor interaction, signaling, dose-response, and physiologic
effects.
Concept Exam-ready distinction
Bioavailability (F) fraction of an administered dose reaching systemic circulation unchanged; IV administration is conventionally 100%.
Clearance (CL) volume of plasma from which drug is completely removed per unit time; determines maintenance-dose requirements.
Half-life (t½) time required for plasma concentration to fall by 50%; for first-order elimination, t½ is linked to clearance and volume of distribution.
Volume of distribution (Vd) apparent volume relating amount of drug in body to plasma concentration; large Vd often reflects extensive tissue distribution.
First-pass effect presystemic metabolism in gut wall/liver that can reduce oral bioavailability.
Therapeutic index conceptual measure comparing toxic and effective exposure; narrow therapeutic-index drugs require closer monitoring.
Agonist activates a receptor and produces a response.
Antagonist binds without activating the receptor and reduces agonist effects.
Partial agonist activates receptor but produces less maximal effect; can function as a functional antagonist in presence of a full agonist.
Potency vs efficacy potency = dose/concentration needed for an effect; efficacy = maximal effect the drug can produce.
3. RECEPTORS, SIGNALING & DOSE–RESPONSE
• Competitive antagonism: increasing agonist concentration can overcome blockade in the classic reversible model; the
dose-response curve shifts right with little change in maximal efficacy.
• Noncompetitive/irreversible antagonism: maximal response may fall because available functional receptor signaling is
reduced.
Goodman & Gilman 13e — Original Enhanced Study Guide Page 2
Enhanced Original Pharmacology Study Guide
High-yield review • mechanisms • therapeutic reasoning • exam-style practice
Based on the publicly visible preview and chapter framework of the referenced Stuvia listing, plus authoritative
drug-development/labeling context.
This is an original study guide. It does not reproduce or reconstruct the paid test bank, and none of the practice questions below are claimed to be
actual or verified exam questions.
Prepared: September 2026
Goodman & Gilman 13e — Original Enhanced Study Guide Page 1
, 1. MASTER EXAM BLUEPRINT
The referenced listing describes an 810-page, 2020/2021 test-bank document and its public preview begins with Chapter 1. The
visible preview emphasizes pharmacology foundations, controlled-drug scheduling, clinical-trial phases, generic
substitution/bioavailability, medication reconciliation, and continuing pharmacology education. ■cite■turn0view0■
The 13th edition itself is organized into nine major sections and 71 chapters, spanning general principles, neuropharmacology,
cardiovascular/renal/pulmonary therapy, inflammation and hematopoiesis, hormones, GI therapy, anti-infective chemotherapy,
cancer pharmacotherapy, and special systems. ■cite■turn0search0■turn1search3■
Section High-yield domains
I. General Principles drug development; PK; PD; toxicity; transporters; metabolism; pharmacogenetics
II. Neuropharmacology autonomic drugs; CNS transmitters; depression/anxiety; psychosis; epilepsy; degeneration; opioids; anesthesia
III. Renal/Cardio/Pulmonary diuretics; RAAS; ischemia; hypertension; heart failure; arrhythmias; PAH; coagulation; lipids
IV. Inflammation/Immune immunosuppression; vaccines; eicosanoids; NSAIDs; histamine; pulmonary drugs; hematopoiesis
V. Endocrine pituitary; thyroid; reproductive hormones; adrenal steroids; diabetes; bone/mineral drugs
VI. GI acid/ulcer/GERD; motility; emesis; biliary/pancreatic disease; IBD
VII. Infectious disease antimicrobial principles; malaria; protozoa; helminths; antibacterials; TB; fungi; viruses; HIV
VIII. Cancer cytotoxic agents; targeted therapy; monoclonal antibodies; kinase inhibitors; endocrine therapy
IX. Special systems ocular; dermatologic; environmental toxicology
2. GENERAL PRINCIPLES: THE CORE LANGUAGE OF
PHARMACOLOGY
Pharmacokinetics (PK) asks what the body does to the drug: absorption, distribution, metabolism, and excretion.
Pharmacodynamics (PD) asks what the drug does to the body: receptor interaction, signaling, dose-response, and physiologic
effects.
Concept Exam-ready distinction
Bioavailability (F) fraction of an administered dose reaching systemic circulation unchanged; IV administration is conventionally 100%.
Clearance (CL) volume of plasma from which drug is completely removed per unit time; determines maintenance-dose requirements.
Half-life (t½) time required for plasma concentration to fall by 50%; for first-order elimination, t½ is linked to clearance and volume of distribution.
Volume of distribution (Vd) apparent volume relating amount of drug in body to plasma concentration; large Vd often reflects extensive tissue distribution.
First-pass effect presystemic metabolism in gut wall/liver that can reduce oral bioavailability.
Therapeutic index conceptual measure comparing toxic and effective exposure; narrow therapeutic-index drugs require closer monitoring.
Agonist activates a receptor and produces a response.
Antagonist binds without activating the receptor and reduces agonist effects.
Partial agonist activates receptor but produces less maximal effect; can function as a functional antagonist in presence of a full agonist.
Potency vs efficacy potency = dose/concentration needed for an effect; efficacy = maximal effect the drug can produce.
3. RECEPTORS, SIGNALING & DOSE–RESPONSE
• Competitive antagonism: increasing agonist concentration can overcome blockade in the classic reversible model; the
dose-response curve shifts right with little change in maximal efficacy.
• Noncompetitive/irreversible antagonism: maximal response may fall because available functional receptor signaling is
reduced.
Goodman & Gilman 13e — Original Enhanced Study Guide Page 2
